Boehringer Ingelheim announces collaboration with MabGenesis
Boehringer Ingelheim announces collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine
Search
Our Innovation Strategy
A deep understanding of disease, identifying relevant mechanisms and choosing therapeutic modalities to address them is the core of our innovation strategy
Partnering in Biotherapeutics MAY 2023 Corp
Partnering in Biotherapeutics JUNE 2023 CORP
Biotherapeutics Modalities Infographic FINAL.pdf
Partnering in Biotherapeutics Technologies MARCH 2023 Corporate
Partnering in Biotherapeutics Technologies MARCH 2023 Corporate
Partnering in Biotherapeutics MAY 2024 CORP .pdf
Immunology Respiratory Research
Find out more about our research and development in Immunology & Respiratory diseases
Veterinary oncology experts meet in Germany
Veterinary oncology experts meet prior to the European Society of Veterinary Oncology Congress in Hofheim, Germany
Immunology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in immunology.
New Therapeutic Antibody Discovery Collaboration
Proprietary antibody libraries to help discover therapeutic antibodies against multiple targets
Research Beyond Borders Partnering
Our Research Beyond Borders team is looking for emerging science and technology opportunities. Learn more about partnering with us.
T-cell engagers: Reawakening T-cells to fight cancer
Learn how we are taking cancer on through our approach to immuno-oncology and our T-cell engagers plarform
2020-Positive-business-momentum-despite-COVID-19-impact
While stepping up its investments in R&D significantly, Boehringer Ingelheim achieved a solid business performance in 2020 despite the COVID-19 pandemic.
Oncology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
Martin Stefanic
Martin Stefanic, Patient Safety Therapeutic Area Head for Oncology, discusses his move to Patient Safety.
Strategic-collaboration-with-EnaraBio
Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.
clinical-collaboration-with-Amgen
Collaboration to study Boehringer Ingelheim’s SOS1::pan-KRAS Inhibitor in combination with Amgen’s KRASG12C Inhibitor
Generalized pustular psoriasis: Value of community support
Dr Clerisme-Beaty and Dr Strober MD, PhD discuss the importance of knowledge sharing, community support and challenges faced by those living with GPP.
Immunomodulator
Immunomodulator
STING agonist (2nd generation)
Second generation STING agonist
Partnership for new liver disease treatments with Ribo
Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases
TREM-1 Antibody
TREM-1 Antibody
Ezabenlimab
Ezabenlimab, PD-1 antibody